Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer
| Autor: | Xianhong Liu, Yunpeng Liu, Shuang Zhang, Chunjiao Wu, Hui Li, Ying Cheng, Yi Liu, Hui-Zheng Bao, Xiaoqing Liu, Yun Fan, Ying Liu, Lixia Ma, Jingjing Liu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Pathology Lung Neoplasms medicine.medical_treatment Cell Count Disease 03 medical and health sciences 0302 clinical medicine Circulating tumor cell Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans In patient Neoplasm Metastasis Lung cancer neoplasms Aged Neoplasm Staging Chemotherapy business.industry General Medicine Middle Aged Neoplastic Cells Circulating Prognosis medicine.disease Small Cell Lung Carcinoma 030104 developmental biology ROC Curve Multicenter study 030220 oncology & carcinogenesis Female business Outcome prediction Extensive-stage small cell lung cancer |
| Zdroj: | Future Oncology. 12:789-799 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aims: As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC. Materials & methods: Blood CTC counts were determined using the CellSearch® system at baseline, after the second cycle of chemotherapy, and on disease progression. Results & conclusion: Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy ≤3 months) and sensitive disease (response to initial therapy >3 months). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|